期刊文献+

表皮生长因子受体抑制剂增敏奈达铂的细胞杀伤作用及机制 被引量:2

Sensibilization of cell-killing effect of nedaplatin by epidermal growth factor receptor inhibitor and the mechanism
原文传递
导出
摘要 目的:探讨表皮生长因子受体(EGFR)特异性抑制剂西妥昔单抗(C225)以及与化疗药物奈达铂(NDP)联合应用对宫颈癌He La细胞的杀伤作用,并分析其作用机制。方法:培养宫颈癌He La细胞;实验分为C225单药组(10、20、40、60、80和160 mg/L)、NDP单药组(1、5、10、20、40和60 mg/L)、C225+NDP联合用药组(C225 40 mg/L分别联合NDP各浓度),每个浓度作用He La细胞后分别培养24、48和72 h后采用MTT法检测细胞抑制率;采用流式细胞术检测细胞凋亡和周期。结果:C225单药不能明显抑制He La细胞增殖;NDP单药对hela细胞有明显抑制作用,C225联合NDP的细胞抑制率明显高于对应的C225或NDP单药(P<0.05)。NDP和C225单独应用均有促进细胞凋亡的作用,联合用药后凋亡率均大于对应的NDP或C225单药(P均<0.05)。NDP或C225单药时,G0-G1期细胞百分比较对照组增加,S期较对照组减少,两药联合后,G0-G1期细胞百分比明显增加(P<0.05),S期细胞百分比明显降低(P<0.05),细胞增殖指数(PI)也逐渐降低(P<0.05)。结论:C225可增强hela细胞对NDP的敏感性,增加细胞凋亡率,G0-G1期阻滞作用增强。 Objective: To explore the cell- killing effect of joint application of epidermal growth factor receptor inhibitor─cetuximab( C225) and chemotherapeutic drug─nedaplatin( NDP) on cervical cancer He La cells,analyze the mechanism. Methods: Cervical cancer He La cells were cultured and divided into C225 group( 10,20,40,60,80 and 160 mg / L),NDP group( 1,5,10,20,40 and60 mg / L) and drug combination group( C225 40 mg / L combined with NDP of different concentrations); cervical cancer He La cells were treated with C225 and NDP of different concentrations and cultured for 24,48 and 72 hours,respectively; MTT assay was used to detect the apoptotic rate; flow cytometry was used to detect cell apoptosis and cycle. Results: C225 could not inhibit proliferation of cervical cancer He La cells significantly; NDP could inhibit proliferation of cervical cancer He La cells significantly; the cell inhibiting rate of C225 combined with NDP was significantly higher than those of simple C225 and simple NDP( P〈0. 05). NDP and C225 used separately could promote cell apoptosis,the apoptotic rate of drug combination of NDP and C225 was statistically significantly higher than that of single NDP and single C225( P〈0. 05). The proportions of He La cells of stage G0 and stage G1 in NDP group and C225 group were higher than those in control group,the proportions of He La cells of stage S in NDP group and C225 group were lower than that in control group,the proportions of He La cells of stage G0 and stage G1 in drug combination group increased significantly( P〈0. 05),while the proportion of He La cells of stage S decreased significantly( P〈0. 05),the proliferation index decreased gradually( P〈0. 05). Conclusion: C225 can strengthen the sensitivity of He La cells to NDP,increase cell apoptotic rate and enhance retardation of stages G0 and G1.
出处 《中国妇幼保健》 CAS 北大核心 2014年第36期6109-6111,共3页 Maternal and Child Health Care of China
关键词 西妥昔单抗 奈达铂 宫颈癌 HELA细胞 Cetuximab Nedaplatin Cervical cancer HeLa cell
  • 相关文献

参考文献6

二级参考文献33

  • 1卢丽霞,赵充,韩非,吴少雄,卢泰祥,崔念基.鼻咽癌照射靶体积划定的临床探讨[J].中华放射肿瘤学杂志,2005,14(2):81-85. 被引量:24
  • 2王树森,管忠震,向燕群,汪波,林桐榆,姜文奇,张力,张惠忠,侯景辉.鼻咽癌组织中EGFR和p-ERK蛋白表达的检测及意义[J].中华肿瘤杂志,2006,28(1):28-31. 被引量:46
  • 3刘凤安,王秀清.VEGF、EGFR蛋白表达与鼻咽癌浸润和转移[J].山东大学耳鼻喉眼学报,2006,20(3):227-229. 被引量:7
  • 4Adachi M, Shibata A, Hayashi M, et al. Combined Preoperative ther- apy for oral cancer with nedaplatin and radiation [ J]. Gan To Kagaku Ryoho, 2002,29(3) :465 -467.
  • 5Desoize B,Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment [ J ]. Crit Rev oncol Hematol,2002,42 (3) : 317 -325.
  • 6Koenuma M, Kasai H, Uchlda N, et al. Pharmacokinetic correlation between experimental and clinical effects on human nonsmall cell lung cancers of cisdiammineglycolatoplatinum (254-S) and cisdiamminedi- chlomplatinum [ J ]. Anticancer Res, 1995,15 (2) :417 - 421.
  • 7Koshiyama M, Kinezaki M, Uchida T, et al, Chemosensitivity testing of a novel platinum analog, nedaplatin( 254-S), in human gynecological carcinomas: a comparison with cisplatin[ J ]. AnticartcerRes ,2005,25 (6C) :499 -502.
  • 8Kodama J ,Takemoto M ,Seki N ,et al ,Phase I study ofweekly nedapla- tin and concurrent pelvic radiotherapy as adjuvant therapy after radi- cal surgery for cervical cancer [ J ]. Int J Gynecol Cancer, 2008, 18 (5) :1037 - 1041.
  • 9Tanaka T, YukawaK, Umesaki N. Radiation reduces carbo, platin sen- sitivity and cnhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro [ J ]. Eur J Gynaecol Oncol, 2007, 28 ( 5 ) : 352 -355.
  • 10Witton C J,Reeves J R,Going J J,et al.Expression of the HER1-4 family of receptor tyrosine kinases in breast[J].Cancer J Pathol,2003,200:290-297.

共引文献43

同被引文献49

  • 1王利娟,田园,高积勇.宫颈癌预后与表皮生长因子受体蛋白表达关系[J].中国妇幼健康研究,2006,17(4):280-282. 被引量:6
  • 2刘俊丽,陈元,蔡煜,张敏.选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用[J].肿瘤防治研究,2007,34(7):480-482. 被引量:8
  • 3J ema A. Bray F. FerlayJ Global cancer statistics[J]. Ca CancerJ Clin.2011.61(2) :69-90.
  • 4Pecore IIi S.Pasinetti Bv Angioli Rver al. Systemic therapy for gynecological neoplasms: ovary. cervix. and endometrium[J]. Cancer Chemother Bioi Response Modif. 2005,22: 515-544.
  • 5Cerciello F. Riesterer O. Sherweil M, et al, Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix[J]. Gynecol On col, 2007 .106(2) :394-399.
  • 6Vosmik M. LacoJ, Sirak I, et al. Prognostic significance of human papilloma virus (HPV) status and expression of selected markers (HER2/neu , EGFR , VEGF, CD34, p63, p53 and Ki67/ MIB-l) on outcome after Cchemo-lradiotherapy in patients with squamous cell carcinoma of uterine cervix[J]. Pathol On colo Res.2014.20(1):131-137.
  • 7Perez-Regadera I .Sanchez-Munnoz AvDe-la-Cruz I .et al. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy[J]. Am I Clin Onco1.2011.34(4) :395-400.
  • 8Iida K, Nakayama K, Rahman MT, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target[J]. Br I Cancer.2011,105(3) :420-427.
  • 9Giordano G.D' Adda T,Dal Bello B,et al. Clinicopathologic implications of the epidermal growth factor receptor, cyclcoxygenase 2 expression, and human papillomavirus status in squamous cell carcinoma of the uterine cervix in the elderly[J]. Int I Gynecol Cancer, 2011 ,21(2) :337-348.
  • 10Farley I, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced. recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study[J]. Gynecol Oncol,2011 ,121(2) :303-308.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部